Guardant Health, Inc.

Guardant Health, Inc. reported revenue of $982.0 million for fiscal year 2025, representing growth from the prior year. The company incurred a net loss of $416.3 million, with an operating loss of $437.2 million. Key cost drivers included sales and marketing expenses of $494.7 million and research and development expenses of $364.2 million. The balance sheet shows total assets of $2.01 billion, including $378.2 million in cash and cash equivalents and $823.4 million in short-term marketable debt securities. However, the company carries significant debt with convertible senior notes of $1.50 billion, resulting in total liabilities of $2.11 billion and stockholders' deficit of $99.3 million. Cash flow from operations was negative $184.8 million, while financing activities provided $671.1 million primarily from equity offerings and convertible note borrowings. The company's financial position reflects ongoing investment in growth initiatives while managing substantial debt obligations.

Key Takeaways